Parker Waichman LLP Headlines by Topic
Definity and Optison
FDA Updates Definity Optison Warning
Jul 17, 2008
| Parker Waichman LLP
Healthcare providers were notified today about labeling changes for Definity and Optison, micro-bubble contrast agents used in sonograms of the...
Heart Imaging Agents Like Definity and Optison Need More Safety Studies, FDA Panel Says
Jun 25, 2008
| Parker Waichman LLP
Heart imaging contrast agents need to be subjected to more studies in order to insure their safety, a Food & Drug Administration (FDA) advisory...
Definity and Optison Side Effects Still Concern FDA
Jun 23, 2008
| Parker Waichman LLP
Definity and Optison - micro-bubble contrast agents used in sonograms of the heart - are still endangering patients. According to...
Definity, Optison Black Box Warning Revised
May 14, 2008
| Parker Waichman LLP
The Food & Drug Administration (FDA) is watering down its warning about the possible risks of Definity and Optison, micro-bubble contrast agents...
Doctor Disputes FDA Black Box Warning on Ultrasound Contrast Agents
Apr 3, 2008
| Parker Waichman LLP
A controversy has erupted over the safety of ultrasound contrast agents used to diagnose heart defects and malfunctions. Last year, the Food...
Page 1/1
